RenovoRx (RNXT) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

RNXT RenovoRx

Watchlist

1.360
0.0000.00%

Close Nov 26 16:00 ET

1.330
-0.030-2.21%

Pre 08:15 ET

32.64MMarket Cap-2344P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

No Data

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

RenovoRx Announces That The Northwell Health Cancer Institute In New Hyde Park, NY Is Enrolling Patients With Locally Advanced Pancreatic Cancer In The Co's Ongoing Phase III TiGeR-PaC Clinical Trial; NHCI Joins Esteemed Clinical Sites Throughout The...
BenzingaNov 20 08:47 ET
Express News | Northwell Health Cancer Institute Launches Patient Enrollment in Renovorx’s Ongoing Pivotal Phase III Tiger-Pac Clinical Trial
ReutersNov 20 08:45 ET
Positive Outlook for RenovoRx: Promising TIGeR-PaC Phase 3 Trial Results and Innovative Drug Delivery Platform Drive Buy Rating
TipRanksNov 15 10:15 ET · Ratings
RenovoRx | 8-K: RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights
SECNov 14 08:37 ET
Express News | RenovoRx Q3 EPS $(0.10), Inline
BenzingaNov 14 08:23 ET
Express News | RenovoRx Q3 Net Income USD -2.5 Million
ReutersNov 14 08:00 ET

Comments

Mr SLP

Nov 21 14:37

$RenovoRx (RNXT.US)$ $Backblaze (BLZE.US)$ $Exact Sciences (EXAS.US)$ $Elevance Health (ELV.US)$
RNXT SMA200 is $1.20, if we can hold above , that's bullish for sure IMO
But always have that protection in place for the profits !
MORE INFO BELOW 👇
https://chartingdaily.com/delivering-therapy-where-it-matters-now
Communicated disclaimer

Trytosaveabit

Nov 20 07:52

Update

$RenovoRx (RNXT.US)$ Northwell Health Cancer Institute Launches Patient Enrollment in Renovorx’s Ongoing Pivotal Phase III Tiger-Pac Clinical Trial

Jaguar8

Nov 20 07:51

NEWS

$RenovoRx (RNXT.US)$
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
5 minutes ago, 5:45 AM PST
Via GlobeNewswire
The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in the First Half of 2025
Phase III Clinical Trial is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Loc...

Jaguar8

Sep 19 07:32

NEWS

$RenovoRx (RNXT.US)$
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer
LOS ALTOS, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Ripal Gandhi, M.D., FSIR, FSVM will present at the...

Jaguar8

Aug 14 12:05

NEWS

$RenovoRx (RNXT.US)$
RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
RenovoRx (Nasdaq: RNXT) has announced the enrollment of the first patient at the University of Nebraska Medical Center (UNMC) for its ongoing Phase III TIGeR-PaC clinical trial. The study is evaluating RenovoGem™, a novel therapy for Locally Advanced Pancreatic Cancer (LAPC) using the TAMP™ (Trans-Arterial Micro-Perfusion) platform....